Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2019 06:00 ET | Source: Adynxx, Inc.

Adynxx Reports Third Quarter 2019 Financial Results

SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
October 02, 2019 08:00 ET | Source: Adynxx, Inc.

Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic

SAN FRANCISCO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
August 14, 2019 07:00 ET | Source: Adynxx, Inc.

Adynxx Reports Second Quarter 2019 Financial Results

SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
July 22, 2019 06:00 ET | Source: Adynxx, Inc.

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
June 12, 2019 12:32 ET | Source: Adynxx, Inc.

Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice

SAN FRANCISCO, June 12, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
May 10, 2019 06:00 ET | Source: Adynxx, Inc.

Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical

Adynxx announces May 29, 2019 as payment date of previously announced special cash dividend of $1.05 per share to former Alliqua shareholders Adynxx confirms intent to consummate the previously...
May 09, 2019 17:30 ET | Source: Adynxx, Inc.

Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard

SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
May 06, 2019 11:05 ET | Source: Alliqua BioMedical, Inc

Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors

SAN FRANCISCO, May 06, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
May 06, 2019 06:00 ET | Source: Adynxx, Inc.

Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors

SAN FRANCISCO, May 06, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
April 22, 2019 10:06 ET | Source: Alliqua BioMedical, Inc

Alliqua BioMedical CEO Provides Update to Shareholders

LANGHORNE, Pa., April 22, 2019 (GLOBE NEWSWIRE) -- Dear Shareholder: On January 3rd, I wrote a letter updating you, our shareholders, on the status of events that I thought would affect each of...